SEC Form 4 · accession 0000905718-18-000853
Matinas BioPharma Holdings, Inc. · MTNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theresa Matkovits
Officer — Chief Development Officer
Period of report
Oct 15, 2018
Accepted (ET)
Oct 16, 2018 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582554
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $0.79 | Oct 15, 2018 | A | 350,000 | A | — | Oct 15, 2028 | Common Stock | 350,000 | 350,000 | D |
Explanation of responses
- F1The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% on October 25, 2019, and the remaining 75% of the shares will vest in equal monthly installments over the following thirty-six (36) months commencing on November 25, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.